-

02:01:46 AM

OCGN Stock News

OCGN - Ocugen Inc

02/01/23 8:00 AM

Nasdaq : OCGN

managementhigh short

Ocugen Appoints Quan A. Vu as Chief Business Officer

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Quan A. Vu as Chief Business Officer,

RHEA-AI

neutral

01/31/23 8:00 AM

Nasdaq : OCGN

conferenceshigh short

Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive

RHEA-AI

neutral

01/09/23 6:00 AM

Nasdaq : OCGN

clinical trialcovid-19high short

Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met

Study met both co-primary endpoints with robust immune responses COVAXIN ™ was found to be well-tolerated in vaccine-naïve individuals and in individuals previously vaccinated with mRNA vaccines in the United States (U.S.), with no vaccine-related serious adverse events, thrombotic events, or cases

RHEA-AI

negative

12/16/22 6:30 AM

Nasdaq : OCGN

clinical trialhigh short

Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and

RHEA-AI

positive

12/15/22 5:15 PM

Nasdaq : OCGN

high short

Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing

RHEA-AI

very positive

12/13/22 8:00 AM

Nasdaq : OCGN

high short

Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive

RHEA-AI

neutral

12/07/22 8:00 AM

Nasdaq : OCGN

clinical trialhigh short

Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and

RHEA-AI

neutral

11/28/22 7:30 AM

Nasdaq : OCGN

conferenceshigh short

Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company’s Chief Scientific Officer, Arun

RHEA-AI

neutral

11/08/22 7:30 AM

Nasdaq : OCGN

earningshigh short

Ocugen Provides Business Update & Third Quarter 2022 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in the third and final cohort of U.S. Phase 1/2 OCU400 gene therapy clinical trial Expanded product pipeline with OCU500—Ocugen’s mucosal COVID-19 vaccine and OCU410ST for Stargardt disease Completed enrollment of U.S. Phase 2/3

RHEA-AI

neutral

10/27/22 7:30 AM

Nasdaq : OCGN

conferencesearningshigh short

Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

OCGN Data

IndustrySanitary Paper Product Manufacturing
Websiteocugen.com
CeoShankar Musunuri
Security nameOcugen Inc
Issue typecs
SectorManufacturing
Sic code3842
Employees56
Tags
- Health Technology
- Biotechnology
- Pharmaceuticals: Major
- Manufacturing
- Sanitary Paper Product Manufacturing
Address5 Great Valley Pkwy Ste 160
StatePennsylvania
CityMalvern
Zip19355
CountryUS
Phone14843284698

About Ocugen Inc

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Its breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug - "one to many" and its novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. The Company is co-developing Bharat Biotech's COVAXIN™ vaccine candidate for COVID-19 in the U.S. market.